The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy
Open accessAbstract
Ribozyme-directed cleavage of mutant mRNAs appears to be a potentially effective therapeutic measure for dominantly inherited diseases. We previously demonstrated that two ribozymes targeted to the P23H mutation in rhodopsin slow photoreceptor degeneration in transgenic rats for up to 3 months of age when injected before significant degeneration at postnatal day (P) 15. We now have explored whether ribozyme rescue persists at older ages, and whether ribozymes are effective when injected later in the degeneration after significant photoreceptor cell loss. Recombinant adeno-associated virus (rAAV) vectors incorporating a proximal bovine rod opsin promoter were used to transfer either hairpin or hammerhead ribozyme genes to photoreceptors. For the study of long-term survival, rAAV was administered by subretinal injection at P15, and the rats were allowed to live up to 8 months of age. For the study of late-stage gene transfer, rAAV was administered at P30 or P45, when 40–45% of the photoreceptors already had degenerated. Eyes were examined functionally by the electroretinogram and structurally by morphometric analysis. When injected at P15, expression of either ribozyme markedly slowed the rate of photoreceptor degeneration for at least 8 months and resulted in significantly greater electroretinogram amplitudes at least up to P180. When injected at P30 or P45, virtually the same number of photoreceptors survived at P130 as when injected at P15. Ribozyme rescue appears to be a potentially effective, long-term therapy for autosomal dominant retinal degeneration and is highly effective even when the gene transfer is done after significant photoreceptor cell loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [136]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Retinitis pigmentosa. The Friedenwald Lecture.
Berson, E. L. (1993) · PubMed · Cited by 730
Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor
Faktorovich, E. G., Steinberg, R. H., Yasumura, D., Matthes, M. T., & LaVail, M. M. (1990) · Nature · doi:10.1038/347083a0 · Cited by 710
Self-citationLewin, A. S., Drenser, K. A., Hauswirth, W. W., Nishikawa, S., Yasumura, D., Flannery, J. G., & LaVail, M. M. (1998) · Nature Medicine · doi:10.1038/nm0898-967 · Cited by 407
Self-citationEfficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationInfluence of eye pigmentation and light deprivation on inherited retinal dystrophy in the rat
LaVail, M. M., & Battelle, B.-A. (1975) · Experimental Eye Research · doi:10.1016/0014-4835(75)90080-9 · Cited by 334
Self-citationPhotoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy
Bennett, J., Tanabe, T., Sun, D., Zeng, Y., Kjeldbye, H., Gouras, P., & Maguire, A. M. (1996) · Nature Medicine · doi:10.1038/nm0696-649 · Cited by 316
The Structure, Function and Application of the Hammerhead Ribozyme
Birikh, K. R., Heaton, P. A., & Eckstein, F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-3-00001.x · Cited by 276
Bennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Unoki, K., & LaVail, M. M. (1994) · PubMed · Cited by 238
Self-citationBerson, E. L. (1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080010094039 · Cited by 231
Research works printed but not linked: 10
- E L Berson Invest Ophthalmol Visual Sci 34, 1659–1676 (1993).
- M B Gorin, J C S Breitner, P T V M De Jong, G S Hageman, C C W Klaver, M H Kuehn, J M Seddon Mol Vis 5, 29 (1999).
- D J Zack, M Dean, R S Molday, J Nathans, T M Redmond, E M Stone, A Swaroop, D Valle, B H Weber Mol Vis 5, 30 (1999).
- M Akimoto, S Miyatake, J Kogishi, M Hangai, K Okazaki, J C Takahashi, M Saiki, M Iwaki, Y Honda Invest Ophthalmol Visual Sci 40, 273–279 (1999).
- J J Rossi Ciba Found Symp 209, 195–204 (1997).
- P A Pavco, K S Bouhana, A M Gallegos, A Agrawal, K S Blanchard, S L Grimm, K L Jensen, L E Andrews, F E Wincott, P A Pitot, et al. Clin Cancer Res 6, 2094–2103 (2000).
- K A Drenser, A M Timmers, W W Hauswirth, A S Lewin Invest Ophthalmol Visual Sci 39, 681–689 (1998).
- K Unoki, M M LaVail Invest Ophthalmol Visual Sci 35, 907–915 (1994).
- J J Michon, Z L Li, N Shioura, R J Anderson, M O M Tso Invest Ophthalmol Visual Sci 32, 280–284 (1991).
- J Bennett, D Duan, J F Engelhardt, A M Maguire Invest Ophthalmol Visual Sci 38, 2857–2863 (1997).
Cited by
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Diseases Caused by Defects in the Visual Cycle: Retinoids as Potential Therapeutic Agents
Travis, G. H., Golczak, M., Moise, A. R., & Palczewski, K. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105225 · Cited by 419
“Viral-mediated expression of ribozymes that targeted the transgene mRNA reduced expression of the mutant rhodopsin and slowed the rate of photoreceptor degeneration (149, 150).”
BackgroundMechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy
Mendes, H. F., van der Spuy, J., Chapple, J. P., & Cheetham, M. E. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.02.007 · Cited by 377
Athanasiou, D., Aguila, M., Bellingham, J., Li, W., McCulley, C., Reeves, P. J., & Cheetham, M. E. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.002 · Cited by 373
Bakondi, B., Lv, W., Lu, B., Jones, M. K., Tsai, Y., Kim, K. J., Levy, R., Akhtar, A. A., Breunig, J. J., Svendsen, C. N., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.220 · Cited by 296
Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk
Vollrath, D., Feng, W., Duncan, J. L., Yasumura, D., D'Cruz, P. M., Chappelow, A., Matthes, M. T., Kay, M. A., & LaVail, M. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221364198 · Cited by 290
Self-citationSakami, S., Maeda, T., Bereta, G., Okano, K., Golczak, M., Sumaroka, A., Roman, A. J., Cideciyan, A. V., Jacobson, S. G., & Palczewski, K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209759 · Cited by 291
Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78
Gorbatyuk, M. S., Knox, T., LaVail, M. M., Gorbatyuk, O. S., Noorwez, S. M., Hauswirth, W. W., Lin, J. H., Muzyczka, N., & Lewin, A. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911991107 · Cited by 279
“Our study also highlights Gorbatyuk et al. PNAS | March 30, 2010 | vol. 107 | no. 13 | 5965 M ED IC A L SC IE N CE S pathways that could be targets for gene therapy or pharmacologic therapy forhumanADRP.”
BackgroundSelf-citationA comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Self-citationJacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224
Self-citationWen, R., Tao, W., Li, Y., & Sieving, P. A. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.005 · Cited by 213
“protect photoreceptors in rhodopsin mutation induced degeneration (Drenser et al., 1998; Lewin et al., 1998; LaVail et al., 2000).”
BackgroundBok, D., Yasumura, D., Matthes, M. T., Ruiz, A., Duncan, J. L., Chappelow, A. V., Zolutukhin, S., Hauswirth, W., & LaVail, M. M. (2002) · Experimental Eye Research · doi:10.1006/exer.2002.1176 · Cited by 213
Self-citationWeber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Chérel, Y., Chenuaud, P., Samulski, J., Moullier, P., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00098-4 · Cited by 203
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“Several groups have attempted to preferentially suppress the production of mutant alleles using small RNA technology including ribozymes (LaVail et al., 2000; Lewin et al., 1998) and short-hairpin (sh) RNAs (Tessitore et al., 2006).”
BackgroundInfluentialPunzo, C., Xiong, W., & Cepko, C. L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.304428 · Cited by 183
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“Improved retinal function and survival of rods was observed even at 8 months of age (LaVail et al. 2000).”
BackgroundMutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector
Cideciyan, A. V., Sudharsan, R., Dufour, V. L., Massengill, M. T., Iwabe, S., Swider, M., Lisi, B., Sumaroka, A., Marinho, L. F., Appelbaum, T., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805055115 · Cited by 147
“These include the hP23H mouse (5, 41, 43), the hP347S mouse (36, 38, 42, 55), and the mP23H (lines 1 and 3) rat (22, 23, 25, 26, 33).”
Self-citationAnimal models in research on retinal degenerations: past progress and future hope
Chader, G. J. (2002) · Vision Research · doi:10.1016/s0042-6989(01)00212-7 · Cited by 147
Jacobson, S. G., Boye, S. L., Alemán, T. S., Conlon, T. J., Zeiss, C. J., Román, A. J., Cideciyan, A. V., Schwartz, S., Komáromy, A. M., Doobrajh, M., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.845 · Cited by 157
Self-citationKhani, S. C., Pawlyk, B. S., Bulgakov, O. V., Kasperek, E. M., Young, J. E., Adamian, M., Sun, X., Smith, A. J., Ali, R. R., & Li, T. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0257 · Cited by 143
Giannelli, S. G., Luoni, M., Castoldi, V., Massimino, L., Cabassi, T., Angeloni, D., Demontis, G. C., Leocani, L., Andreazzoli, M., & Broccoli, V. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx438 · Cited by 143
“In the past, various paradigms of gene inactivation have been taken into consideration for Rho inactivation with variable degrees of specificity and efficacy: ribozymes (29,30), short hairpin RNAs (31,32), zinc-finger nuclease (33).”
BackgroundSeeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Chadderton, N., Millington‐Ward, S., Palfi, A., O’Reilly, M., Tuohy, G., Humphries, M. M., Li, T., Humphries, P., Kenna, P. F., & Farrar, G. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.301 · Cited by 133
Clinical applications of retinal gene therapy
Lipinski, D. M., Thake, M., & MacLaren, R. E. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.001 · Cited by 132
“Ribozymes are catalytic RNA molecules with developed tertiary structures which allow them to bind and directly cleave complementary mRNA sequences, and have been shown to significantly reduce expression of mutant P23H rhodopsin protein when expressed from rAAV vectors (Drenser et al., 1998; Gorbatyuk et al., 2007; Hau…”
BackgroundNeuroprotective Effect of Subretinal Implants in the RCS Rat
Pardue, M. T., Phillips, M. J., Yin, H., Sippy, B. D., Webb-Wood, S., Chow, A. Y., & Ball, S. L. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0515 · Cited by 119
“It may be possible to obtain even greater protective effects from subretinal electrical stimulation by increasing the output from the ASR by (1) altering the ASR design to increase current levels or ( 2 ) driving existing ASRs to produce higher levels of stimulation by increasing environmental light levels.”
BackgroundGopalan, V., Vioque, A., & Altman, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100067200 · Cited by 117
Inherited retinal degenerations: therapeutic prospects
Delyfer, M., Léveillard, T., Mohand‐Saïd, S., Hicks, D., Picaud, S. A., & Sahel, J. (2004) · Biology of the Cell · doi:10.1111/j.1768-322x.2004.tb01414.x · Cited by 125
“LaVail’s research group examined the potential effects of ribozyme therapy in the P23H transgenic rat, a model of a very widespread rhodopsin mutation in North America resulting in dominantly inherited retinal degeneration (Lewin et al., 1998; LaVail et al., 2000).”
Ribozyme gene therapy: applications for molecular medicine
Lewin, A. S., & Hauswirth, W. W. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)01965-7 · Cited by 114
Self-citationMolecular genetics and prospects for therapy of the inherited retinal dystrophies
Bessant, D. A. R., Ali, R. R., & Bhattacharya, S. S. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00195-7 · Cited by 131
Li, P., Kleinstiver, B. P., Leon, M., Prew, M. S., Navarro-Gomez, D., Greenwald, S. H., Pierce, E. A., Joung, J. K., & Liu, Q. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0009 · Cited by 122
“The mutant P23H rhodopsin protein is thought to misfold and co-aggregate with wild-type rhodopsin, resulting in a gain-of-function or dominant negative effect in rod photoreceptor cells.(3,6) In this study, by designing and testing combinations of sgRNAs and Cas9 variants, we have demonstrated effective and specific k…”
BackgroundP23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis
Sakami, S., Kolesnikov, A. V., Kefalov, V. J., & Palczewski, K. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt561 · Cited by 126
Murray, S., Jazayeri, A., Matthes, M. T., Yasumura, D., Yang, H., Peralta, R. Q., Watt, A., Freier, S., Hung, G., Adamson, P., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16400 · Cited by 109
Self-citationAdeno-Associated Virus-Vectored Gene Therapy for Retinal Disease
Dinculescu, A., Glushakova, L. G., Min, S.-H., & Hauswirth, W. W. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.649 · Cited by 109
Self-citationSekirnjak, C., Hulse, C., Jepson, L. H., Hottowy, P., Sher, A., Dąbrowski, W., Litke, A. M., & Chichilnisky, E. J. (2009) · Journal of Neurophysiology · doi:10.1152/jn.00663.2009 · Cited by 104
“Photoreceptor loss progressed somewhat more slowly than previously reported for the P23H-1 line in albino rats (Cuenca et al. 2004; LaVail et al. 2000; Machida et al. 2000).”
BackgroundOptic Neuropathy Induced by Reductions in Mitochondrial Superoxide Dismutase
Qi, X., Lewin, A. S., Hauswirth, W. W., & Guy, J. R. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0864 · Cited by 103
Self-citationDisease Boundaries in the Retina of Patients with Usher Syndrome Caused by MYO7A Gene Mutations
Jacobson, S. G., Aleman, T. S., Sumaroka, A., Cideciyan, A. V., Roman, A. J., Windsor, E. A. M., Schwartz, S. B., Rehm, H. L., & Kimberling, W. J. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3122 · Cited by 93
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Rescue of Photoreceptor Degeneration by Curcumin in Transgenic Rats with P23H Rhodopsin Mutation
Vasireddy, V., Chavali, V. R. M., Joseph, V. T., Kadam, R. S., Lin, J. H., Jamison, J. A., Kompella, U. B., Reddy, G. B., & Ayyagari, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021193 · Cited by 99
“Several other potential therapies for retinal dystrophies are currently under development or evaluation [52,53,54,55].”
BackgroundAlemán, T. S., LaVail, M. M., Montemayor, R., Ying, G., Maguire, M., Laties, A. M., Jacobson, S. G., & Cideciyan, A. V. (2001) · Vision Research · doi:10.1016/s0042-6989(01)00157-2 · Cited by 95
“This is especially surprising since it is well established that the Tg rat rods have abnormally shortened OS length (Lewin et al., 1998; LaVail et al., 2000; Machida et al., 2000).”
Self-citationRetinal ganglion cell numbers and delayed retinal ganglion cell death in the P23H rat retina
García‐Ayuso, D., Salinas‐Navarro, M., Agudo‐Barriuso, M., Cuenca, N., Pinilla, I., Vidal‐Sanz, M., & Villegas‐Pérez, M. P. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.10.003 · Cited by 97
The Nature of Dominant Mutations of Rhodopsin and Implications for Gene Therapy
Wilson, J. H., & Wensel, T. G. (2003) · Molecular Neurobiology · doi:10.1385/mn:28:2:149 · Cited by 96
“A ribozyme that is specific for the mRNA from a P23H allele has been shown to slow retinal degeneration in a rat model (34,35).”
BackgroundPharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye
Auricchio, A., Rivera, V. M., Clackson, T., O'Connor, E. E., Maguire, A. M., Tolentino, M. J., Bennett, J., & Wilson, J. M. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0660 · Cited by 89
Miyazaki, M., Ikeda, Y., Yonemitsu, Y., Goto, Y., Sakamoto, T., Tabata, T., Ueda, Y., Hasegawa, M., Tobimatsu, S., Ishibashi, T., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302028 · Cited by 85
LaVail, M. M., Nishikawa, S., Steinberg, R. H., Naash, M. I., Duncan, J. L., Trautmann, N., Matthes, M. T., Yasumura, D., Lau-Villacorta, C., Chen, J., et al. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.10.023 · Cited by 93
“For instance, the P23H lines would be used if an approach attempts to modify mutant P23H alleles or knock down the P23H rhodopsin, such as the use of a P23H-directed ribozyme in either an allele-specific (LaVail et al., 2000; Lewin et al., 1998) or allele-independent (Gorbatyuk et al.”
Self-citationGorbatyuk, M. S., Justilien, V., Liu, J., Hauswirth, W. W., & Lewin, A. S. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.08.014 · Cited by 85
“Although we have taken special precautions, such as removing bulbs from the overhead lighting and shielding the tops of the racks to reduce their exposure, the erosion of the ERG response was faster in the P23H line 3 animals used in this experiment than we had previously seen in the animals of the same line housed at…”
MethodResultSelf-citationSuppression of complex I gene expression induces optic neuropathy
Qi, X., Lewin, A. S., Hauswirth, W. W., & Guy, J. R. (2003) · Annals of Neurology · doi:10.1002/ana.10426 · Cited by 84
Self-citationBeyond mitomycin: TGF-β and wound healing
Cordeiro, M. F. (2002) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00021-0 · Cited by 87
Custom CRISPR–Cas9 PAM variants via scalable engineering and machine learning
Silverstein, R. A., Kim, N., Kroell, A.-S. H., Walton, R. T., Delano, J., Butcher, R. M., Pačesa, M., Smith, B., Christie, K. A., Ha, L. L., et al. (2025) · Nature · doi:10.1038/s41586-025-09021-y · Cited by 91
“As a dominant negative mutation, knockout of the mutant allele while leaving the wild-type allele intact can rescue function in heterozygous genotypes 60,61 .”
Pearce-Kelling, S. E., Alemán, T. S., Nickle, A., Laties, A. M., Aguirre, G., Jacobson, S. G., & Acland, G. M. (2001) · PubMed · Cited by 83
Advances in gene therapy technologies to treat retinitis pigmentosa
Petrs‐Silva, H., & Linden, R. (2013) · Clinical ophthalmology · doi:10.2147/opth.s38041 · Cited by 94
“74,75 These results were the first evidence that gene-silencing approaches for disease correction can be effective for long-term therapy in autosomal-dominant retinal degeneration.”
Mussolino, C., Sanges, D., Marrocco, E., Bonetti, C., Vicino, U. D., Marigo, V., Auricchio, A., Meroni, G., & Surace, E. M. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201000119 · Cited by 78
“In particular, RNA interference (RNAi) has great promise for treating dominant diseases in both mutationdependent and -independent manners, through its efficiency of mRNA transcript cleavage (LaVail et al, 2000; Lewin et al, 1998; O’Reilly et al, 2007; Xia et al, 2004).”
BackgroundRetinitis Pigmentosa and Allied Diseases
Berson, E. L. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-0016-7.50180-6 · Cited by 73
Neurotrophic Signaling in Normal and Degenerating Rodent Retinas
Wahlin, K. J., Adler, R., Zack, D. J., & Campochiaro, P. A. (2001) · Experimental Eye Research · doi:10.1006/exer.2001.1078 · Cited by 72
IRE1 directs proteasomal and lysosomal degradation of misfolded rhodopsin
Chiang, W.-C. J., Messah, C., & Lin, J. H. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-08-0663 · Cited by 82
“Alternatively, ribozyme-mediated degradation of P23H rhodopsin mRNA that spared wild-type rhodopsin has also shown efficacy in enhancing photoreceptor cell survival in transgenic animals expressing mutant and wild-type rhodopsins (Lewin et al., 1998; LaVail et al., 2000).”
BackgroundPierdomenico, J. D., Scholz, R., Valiente‐Soriano, F. J., Sánchez-Migallón, M. C., Vidal‐Sanz, M., Langmann, T., Agudo‐Barriuso, M., García‐Ayuso, D., & Villegas‐Pérez, M. P. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24621 · Cited by 74
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 77
“Different groups tried to suppress the production of the dominant mutant allele by AAV-mediated expression of short-hairpin (sh) RNAs [111] or ribozymes [112,113].”
BackgroundGenetics and molecular pathology of Stargardt-like macular degeneration
Vasireddy, V., WONG, P. W. K., & Ayyagari, R. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.01.001 · Cited by 72
“Inhibition of mutant gene expression can be achieved by a variety of approaches, including antisense, ribozymes, and, more recently, RNA interference (RNAi) (Hauswirth et al., 2000; LaVail et al., 2000; Bumcrot et al., 2006; Zimmermann et al., 2006).”
BackgroundMutations in PRPF31 Inhibit Pre-mRNA Splicing of Rhodopsin Gene and Cause Apoptosis of Retinal Cells
Yuan, L., Kawada, M., Havlioglu, N., Tang, H., & Wu, J. Y. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2399-04.2005 · Cited by 83
“, 2002), delivery of genes to produce photoreceptor trophic factors, application of ribozymes to suppress the expression of disease-causing or disease-inducing genes, and therapies aimed at reducing photoreceptor cell death (LaVail et al., 2000; Bennett, 2002; Chaum and Hatton, 2002).”
BackgroundNeuroprotective Strategies for the Treatment of Inherited Photoreceptor Degeneration
Trifunović, D., Sahaboglu, A., Kaur, J., Mencl, S., Zrenner, E., Ueffing, M., Arango‐González, B., & Paquet‐Durand, F. (2012) · Current Molecular Medicine · doi:10.2174/156652412800620048 · Cited by 71
A Morphometric Study of Light-Induced Damage in Transgenic Rat Models of Retinitis Pigmentosa
Merriman, D. K., Coulibaly, S. F., Darrow, R. M., & Organisciak, D. T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0709 · Cited by 69
Wang, S., Lü, B., Girman, S. V., Holmes, T. M., Bischoff, N., & Lund, R. D. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0992 · Cited by 67
DeMarco, P. J., Yarbrough, G. L., Yee, C. W., McLean, G. Y., Sagdullaev, B. T., Ball, S. L., & McCall, M. A. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-0811 · Cited by 65
Increased Sensitivity to Light-Induced Damage in a Mouse Model of Autosomal Dominant Retinal Disease
White, D. A., Hauswirth, W. W., Kaushal, S., & Lewin, A. S. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-1131 · Cited by 66
Self-citationProgress in the Use of Adeno-Associated Viral Vectors for Gene Therapy
Büning, H., Braun‐Falco, M., & Hallek, M. J. (2004) · Cells Tissues Organs · doi:10.1159/000079988 · Cited by 76
“The successful rescue of a dominant rhodopsin mutation in rat photoreceptor cells through rAAV-2-mediated ribozymes has already been demonstrated [LaVail et al., 2000].”
BackgroundPlasticity in the Visual System
Pinaud, R., Tremere, L. A., & Weerd, P. D. (2006) · Springer eBooks · doi:10.1007/0-387-28190-8 · Cited by 61
Animal models and different therapies for treatment of retinitis pigmentosa.
Rivas, M. A., & Vecino, E. (2009) · PubMed · doi:10.14670/hh-24.1295 · Cited by 76
Palfi, A., Millington‐Ward, S., Chadderton, N., O’Reilly, M., Goldmann, T., Humphries, M. M., Li, T., Wolfrum, U., Humphries, P., Kenna, P. F., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.119 · Cited by 59
García‐Ayuso, D., Ortín-Martínez, A., Jiménez-López, M., Galindo‐Romero, C., Cuenca, N., Pinilla, I., Vidal‐Sanz, M., Agudo‐Barriuso, M., & Villegas‐Pérez, M. P. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12643 · Cited by 58
Inherent Instability of the Retinitis Pigmentosa P23H Mutant Opsin
Chen, Y., Jastrzębska, B., Cao, P., Zhang, J., Wang, B., Sun, W., Yuan, Y., Feng, Z., & Palczewski, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551713 · Cited by 64
“the most commonly used animal model for gene therapy and drug testing (12,21,22,77-83) but immunochemistry showed rhodopsin is localized in the ROS of this TG rat (84).”
Modulation of cellular signaling pathways in P23H rhodopsin photoreceptors
Sizova, O. S., Shinde, V. M., Lenox, A. R., & Gorbatyuk, M. S. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2013.12.008 · Cited by 63
Pierdomenico, J. D., García‐Ayuso, D., Pinilla, I., Cuenca, N., Vidal‐Sanz, M., Agudo‐Barriuso, M., & Villegas‐Pérez, M. P. (2017) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2017.00014 · Cited by 60
Retinopathy of Prematurity: Molecular Pathology and Therapeutic Strategies
Mechoulam, H., & Pierce, E. A. (2003) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200303040-00004 · Cited by 56
The Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 59
AAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based hairpins
Georgiadis, A., Tschernutter, M., Bainbridge, J. W., Robbie, S. J., McIntosh, J., Nathwani, A. C., Smith, A. J., & Ali, R. R. (2009) · Gene Therapy · doi:10.1038/gt.2009.162 · Cited by 58
Gorbatyuk, M. S., Starr, C. R., & Gorbatyuk, O. S. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100860 · Cited by 55
“By contrast, P23H RHO transgenic rats show greater involvement of the superior retina (LaVail et al., 2000).”
BackgroundGenotypic and Phenotypic Characterization of P23H Line 1 Rat Model
Orhan, E., Dalkara, D., Neuillé, M., Lechauve, C., Michiels, C., Picaud, S. A., Léveillard, T., Sahel, J., Naash, M. I., LaVail, M. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127319 · Cited by 60
“P23H rat models were developed for translational research and study photoreceptor rescue strategies [23, 24].”
BackgroundSelf-citationGlybina, I. V., Kennedy, A., Ashton, P., Abrams, G. W., & Iezzi, R. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4492 · Cited by 54
Current Concepts in the Treatment of Retinitis Pigmentosa
Musarella, M. A., & MacDonald, I. M. (2010) · Journal of Ophthalmology · doi:10.1155/2011/753547 · Cited by 60
Gene Transfer to the Nonhuman Primate Retina with Recombinant Feline Immunodeficiency Virus Vectors
Lotery, A. J., Derksen, T. A., Russell, S. R., Mullins, R. F., Sauter, S. L., Affatigato, L. M., Stone, E. M., & Davidson, B. L. (2002) · Human Gene Therapy · doi:10.1089/104303402317322258 · Cited by 53
Gene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 59
“Allele-dependent approaches have used AAV-mediated delivery of either mutation-specific ribozymes (Lewin et al., 1998; LaVail et al., 2000) or shorthairpin (sh) RNAs (Tessitore et al., 2006) directed to the common P23H-RHO mutation.”
BackgroundGlybina, I. V., Kennedy, A., Ashton, P., Abrams, G. W., & Iezzi, R. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2831 · Cited by 51
Cone-specific expression using a human red opsin promoter in recombinant AAV
Li, Q., Timmers, A. M., Guy, J. R., Pang, J., & Hauswirth, W. W. (2007) · Vision Research · doi:10.1016/j.visres.2007.07.026 · Cited by 50
“(2) Allele-specific targeting for dominant-negative mutations , such as anti-P23H rod opsin ribozymes delivered by recombinant adeno-associated virus preserved photoreceptors for more than three months in a transgenic rat model for P23H RP (LaVail et al., 2000).”
BackgroundSelf-citationThe use of canine models of inherited retinal degeneration to test novel therapeutic approaches
Beltran, W. A. (2009) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2009.00694.x · Cited by 55
Chapter 1 Rhodopsin‐Mediated Retinitis Pigmentosa
Malanson, K. M., & Lem, J. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)88001-0 · Cited by 54
Gene Therapy of Inherited Retinal Degenerations: Prospects and Challenges
Trapani, I., Banfi, S., Simonelli, F., Surace, E. M., & Auricchio, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.030 · Cited by 55
Adamus, G., Sugden, B., Shiraga, S., Timmers, A. M., & Hauswirth, W. W. (2003) · Journal of Autoimmunity · doi:10.1016/s0896-8411(03)00092-1 · Cited by 50
Self-citationNour, M., Quiambao, A. B., Peterson, W. M., Al‐Ubaidi, M. R., & Naash, M. I. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0453 · Cited by 45
McGill, T. J., Prusky, G. T., Douglas, R. M., Yasumura, D., Matthes, M. T., Lowe, R. J., Duncan, J. L., Yang, H., Ahern, K., Daniello, K. M., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9569 · Cited by 47
Self-citationAAV-mediated gene transfer for retinal diseases
Allocca, M., Tessitore, A., Cotugno, G., & Auricchio, A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.12.1279 · Cited by 50
“Inhibition of gene expression P23H ribozymes P23H siRNA P23H rat P23H rat RP RP [116,117]”
BackgroundMethodRNA Interference-Based Therapy for Spinocerebellar Ataxia Type 7 Retinal Degeneration
Ramachandran, P. S., Bhattarai, S., Singh, P., Boudreau, R. L., Thompson, S., LaSpada, A. R., Drack, A. V., & Davidson, B. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095362 · Cited by 44
“strategies using ribozymes, RNA enzymes that cleave specific mRNA molecules, demonstrated delayed photoreceptor degeneration in a rat model of autosomal dominant retinitis pigmentosa [18,19].”
BackgroundAdeno-associated viral vectors for retinal gene transfer
Surace, E. M., & Auricchio, A. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(03)00052-1 · Cited by 47
Athanasiou, D., Aguilà, M., Opefi, C. A., South, K., Bellingham, J., Bevilacqua, D., Munro, P., Kanuga, N., Mackenzie, F. E., Dubis, A. M., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw387 · Cited by 52
“As reported previously, the superior retina of P23H-1 rats was more damaged than the inferior (43); however, metformin treatment caused a reduction in the thickness of the ONL in the inferior retina compared to the ONL thickness of vehicle-treated rats (Fig.”
BackgroundGenetic manipulation for inherited neurodegenerative diseases: myth or reality?
Yu‐Wai‐Man, P. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308329 · Cited by 45
Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration
Souied, E. H., Reid, S. N. M., Piri, N., Lerner, L. E., Nusinowitz, S., & Farber, D. B. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.04.009 · Cited by 43
“…pigment epithelium and photoreceptor cells, application of trophic growth factors, cell-based delivery of neurotrophic factors and ribozyme therapy have been attempted for these blinding disorders (Berson et al., 1993; Frasson et al., 1999; Kumar-Singh and Farber, 1998; LaVail et al., 2000).”
BackgroundGene Therapy and Animal Models for Retinal Disease
Dejneka, N. S., Rex, T. S., & Bennett, J. (2003) · KARGER eBooks · doi:10.1159/000072047 · Cited by 47
Gene Augmentation for adRP Mutations in RHO
Lewin, A. S., Rossmiller, B. P., & Mao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017400 · Cited by 44
“Although allele specific knockdown of P23H mRNA reduced the rate of retinal degeneration in P23H Rho transgenic rats over a prolonged period (LaVail et al. 2000), the large number of different adRP mutations in RHO make this approach challenging, because a different inhibitor would be needed for…”
BackgroundSelf-citationTessitore, A., Parisi, F., Denti, M. A., Allocca, M., Vicino, U. D., Domenici, L., Bozzoni, I., & Auricchio, A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.07.008 · Cited by 46
“Allele-specific inhibition of the P23H rhodopsin has been recently obtained in vivo using ribozymes delivered to photoreceptors via adenoassociated viral (AAV) vectors [18,19].”
Rhodopsin-associated retinal dystrophy: Disease mechanisms and therapeutic strategies
Zhen, F., Zou, T., Wang, T., Zhou, Y., Dong, S., & Zhang, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1132179 · Cited by 44
“Ribozyme, zinc-finger–based artificial transcription factors, and RNAi have been utilized to suppress the expression of endogenous target genes (LaVail et al., 2000; Jiang et al., 2011; Mussolino et al., 2011).”
Terrada, C., Fisson, S., De Kozak, Y., Kaddouri, M., Lehoang, P., Klatzmann, D., Salomon, B. L., & Bodaghi, B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7171 · Cited by 38
“with recombinant adeno-associated viral (AAV) vector (17, 18).”
MethodTherapeutic gene silencing in the nervous system
Wood, M. J. A., Trülzsch, B., Abdelgany, A., & Beeson, D. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg275 · Cited by 37
“In other experiments, ribozymes targeting the P23H mutation in rhodopsin have been shown to slow photoreceptor degeneration in transgenic rats for prolonged periods (59,60).”
Background
Metadata
- Authors
- LaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A., Flannery, J. G., Lewin, A. S., & Hauswirth, W. W.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-09-26
- Volume
- 97
- Issue
- 21
- Pages
- 11488-11493
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC17227
- OpenAlex
- W2077508733
- Cited by
- 203
- References
- 38
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 5 · 2015: 8 · 2014: 9 · 2013: 6 · 2012: 12
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- March of Dimes Foundation
- Foundation Fighting Blindness
- Research to Prevent Blindness (EY02162)
- Macula Vision Research Foundation
- National Institutes of Health (EY01919, EY02162)
- National Eye Institute (EY-06842, EY02162, P30EY002162, EY-01919, R01EY011596, R01EY001919, P30EY008571, F32EY006842, R01EY011123, R01EY006842, T32EY007132)
- National Institute of Neurological Disorders and Stroke (P01NS036302)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- retinitis pigmentosa, photoreceptor degeneration, adeno-associated virus vectors, hairpin ribozyme, hammerhead ribozyme, transgenic rats, electroretinogram, long-term survival
- MeSH terms
- Animals, Cell Survival, Photoreceptor Cells, Retinal Diseases, Genetic Therapy, RNA, Catalytic, Animals, Genetically Modified, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.